BioTuesdays

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...

PDS Biotechnology Logo

HCW ups PDS Biotechnology to buy; PT $6

H.C. Wainwright upgraded PDS Biotechnology (NASDAQ:PDSB) to “buy” from “neutral” with a price target of $6. The stock closed at $2.04 on Nov. 9. In March 2020, HCW downgraded PDS based on dilution, significantly reduced...

Syros-Logo

Brookline starts Syros Pharma at buy; PT $19

Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...

ObsEva Logo

ObsEva names Brian O’Callaghan as CEO

Brian O’Callaghan ObsEva (NASDAQ:OBSV) appointed Brian O’Callaghan as CEO, effective Dec. 1. He succeeds ObsEva’s co-founder, Ernest Loumaye, M.D., Ph.D., who is retiring from his role as CEO but will remain a...

Codiak-Logo

William Blair starts Codiak BioSciences at OP

William Blair launched coverage of Codiak BioSciences (NASDAQ:CDAK) with an “outperform” rating based on the potential of the company’s novel exosome platform and clinical readouts over the next six-to-nine months...

AVEO Pharmaceuticals Logo

Stifel starts AVEO Pharma at buy; PT $9

Stifel initiated coverage of AVEO Pharmaceuticals (NASDAQ:AVEO) with a “buy” rating and price target of $9. The stock closed at $5.66 on Nov. 6. AVEO is focused on the development and commercialization of targeted...